000169020 001__ 169020
000169020 005__ 20240229133635.0
000169020 0247_ $$2doi$$a10.3324/haematol.2021.278894
000169020 0247_ $$2pmid$$apmid:34047179
000169020 0247_ $$2ISSN$$a0390-6078
000169020 0247_ $$2ISSN$$a1592-8721
000169020 0247_ $$2altmetric$$aaltmetric:106659644
000169020 037__ $$aDKFZ-2021-01188
000169020 041__ $$aEnglish
000169020 082__ $$a610
000169020 1001_ $$aTeich, Katrin$$b0
000169020 245__ $$aCluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin.
000169020 260__ $$aPavia$$bFerrata Storti Found$$c2021
000169020 264_1 $$2Crossref$$3online$$bFerrata Storti Foundation (Haematologica)$$c2021-05-27
000169020 3367_ $$2DRIVER$$aarticle
000169020 3367_ $$2DataCite$$aOutput Types/Journal article
000169020 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642078639_473
000169020 3367_ $$2BibTeX$$aARTICLE
000169020 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169020 3367_ $$00$$2EndNote$$aJournal Article
000169020 500__ $$a2021 Nov 1;106(11):2986-2989
000169020 520__ $$aNot available.
000169020 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169020 542__ $$2Crossref$$i2021-05-27$$uhttps://creativecommons.org/licenses/by-nc/4.0/legalcode
000169020 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169020 7001_ $$0P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aKrzykalla, Julia$$b1$$udkfz
000169020 7001_ $$aKapp-Schwoerer, Silke$$b2
000169020 7001_ $$aGaidzik, Verena I$$b3
000169020 7001_ $$aSchlenk, Richard F$$b4
000169020 7001_ $$aPaschka, Peter$$b5
000169020 7001_ $$aWeber, Daniela$$b6
000169020 7001_ $$aFiedler, Walter$$b7
000169020 7001_ $$aKühn, Michael W M$$b8
000169020 7001_ $$aSchroeder, Thomas$$b9
000169020 7001_ $$aMayer, Karin$$b10
000169020 7001_ $$aLübbert, Michael$$b11
000169020 7001_ $$aRamachandran, Dhanya$$b12
000169020 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b13$$udkfz
000169020 7001_ $$aGanser, Arnold$$b14
000169020 7001_ $$aDöhner, Hartmut$$b15
000169020 7001_ $$aHeuser, Michael$$b16
000169020 7001_ $$aDöhner, Konstanze$$b17
000169020 7001_ $$aThol, Felicitas$$b18
000169020 77318 $$2Crossref$$3journal-article$$a10.3324/haematol.2021.278894$$bFerrata Storti Foundation (Haematologica)$$d2021-05-27$$n11$$p2986-2989$$tHaematologica$$v106$$x1592-8721$$y2021
000169020 773__ $$0PERI:(DE-600)2805244-4$$a10.3324/haematol.2021.278894$$n11$$p2986-2989$$tHaematologica$$v106$$x1592-8721$$y2021
000169020 909CO $$ooai:inrepo02.dkfz.de:169020$$pVDB
000169020 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169020 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000169020 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169020 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169020 9141_ $$y2021
000169020 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-06-12
000169020 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-06-12
000169020 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000169020 980__ $$ajournal
000169020 980__ $$aVDB
000169020 980__ $$aI:(DE-He78)C060-20160331
000169020 980__ $$aUNRESTRICTED
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3324/haematol.2018.188888$$uLambert J, Pautas C, Terré C. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019; 104(1):113-119.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1158/1078-0432.CCR-11-0486$$uRicart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011; 17(20):6417-6427.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2016.71.2513$$uLamba JK, Chauhan L, Shin M. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2017; 35(23):2674-2682.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1517/14712598.2014.922534$$uThol F, Schlenk RF. Gemtuzumab ozogamicin in acute myeloid leukemia revisited. Expert Opin Biol Ther. 2014; 14(8):1185-1195.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1517/14712598.1.5.893$$uSievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther. 2001; 1(5):893-901.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/leu.2017.187$$uGodwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017; 31(9):1855-1868.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(14)70281-5$$uHills RK, Castaigne S, Appelbaum FR. The addition of gemtuzumab ozogamicin to induction chemotherapy in acute myeloid leukaemia: an individual patient data meta-analysis of randomised trials in adults. Lancet Oncol. 2014; 15(9):986-996.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s12185-012-1123-9$$uKühnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int J Hematol. 2012; 96(2):153-163.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.19.01406$$uSchlenk RF, Paschka P, Krzykalla J. Gemtuzumab ozogamicin in NPM1 -mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study. J Clin Oncol. 2020; 38(6):623-632.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/nature05887$$uEaston EF, Pooley KA, Dunning AM. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447(7148):1087-1093.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2011.35.4894$$uThol F, Damm F, Lüdeking A. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011; 29(21):2889-2896.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2016-08-733196$$uDöhner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2009-07-235358$$uDöhner H, Estey EH, Amadori S. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115(3):453-474.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2017-08-802157$$uGale RE, Popa T, Wright M. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. Blood. 2018; 131(4):468-471.
000169020 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/ajh.25854$$uShort NJ, Richard-Carpentier G, Kanagal-Shamanna R. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020; 95(9):E225-E228.